DRAI yields 1.59% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, DRAI + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DRAI + PFE for your $10,000?
DRAI aims for long-term capital appreciation by holding 10-20 ETF positions across a variety of asset classes including US equities, gold, fixed-income securities, and more. The fund uses an AI model trained on historical pricing data to predict short-term market trends and volatility, which influences 70% of its asset selections. This is complemented by a macroeconomic model analyzing data like unemployment insurance applications and interest rate spreads to inform long-term outlooks. Combined, they make up the funds proprietary AI system called the Draco Model. In bearish markets, DRAI leans towards US treasury bonds and inverse ETFs, in bullish markets, it favors US equities and leveraged ETFs. The fund continually rebalances based on daily market conditions and has mechanisms to provide downside protection but may experience increased volatility due to leveraged investments. The Funds sub-adviser has the discretion to override the AI model in extreme circumstances.
Full DRAI Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.